Clinical pharmacokinetics of tretinoin

Clinical Pharmacokinetics

Volumn 32, Issue 5, 1997, Pages 382-402

  Regazzi, Mario B ^a,c   Iacona, Isabella ^a   Gervasutti, Cristina ^a   Lazzarino, Mario ^a   Toma, Salvatore ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTI ACNE AGENT; CELL NUCLEUS RECEPTOR; CYTOCHROME P450 INHIBITOR; LIPOSOME; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN; RETINOL;

ACUTE MYELOBLASTIC LEUKEMIA; ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CATABOLISM; CYTOPLASM; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG OXIDATION; HUMAN; INTESTINE ABSORPTION; INTRAVENOUS DRUG ADMINISTRATION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

EID: 0030915314     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199732050-00004     Document Type: Review

References (111)

1. Cullum ME, Zile MH. Metabolism of all-trans-retinoic acid and all-trans-retinyl acetate. J Biol Chem 1985; 260: 10590-6
2. Degos L, Chomeienne C, Daniel MT, et al. Treatment of first relapse in acute promyelocytic leukemia with all-trans retinoic acid [letter]. Lancet 1990; 336 (8728): 1440-1
3. Castaigne S, Chomeienne C, Daniel MT, et al. All-trans retinoic acid as differentiation therapy for acute promyelocytic leukemia. Blood 1990; 76: 1704-9
4. Warrel RP, Frankel Jr RP, Miller Jr WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 1991; 324 (20): 1385-93
5. Fenaux P, Chastang C, Chomeienne C, et al. Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukemia: European APL group [letter]. Lancet 1994; 343 (8904): 1033
6. Kuzel T, Roenigk H, Samuelson E, et al. The treatment of mycosis fungoides with all-trans retinoic acid [abstract]. Blood 1993; 82: 570a
7. Gill PS, Espina BM, Mougdil T, et al. All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study. Leukemia 1994; 8 (3): S26-32
8. Lippman SM, Kavanagh JJ, Paredes-Espinoza M, et al. 13-cis retinoic acid plus interferon α-2a: highly active systemic therapy for squamous cell carcinoma of the skin. J Natl Cancer Inst 1992; 84 (4): 241-5
9. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis retinoic acid and interferon α-2a effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992; 84 (4): 235-41
10. Athanasiadis I, Kies MS, Miller M, et al. Phase II study of all-trans retinoic acid and interferon α-2a in patients with advanced non-small cell lung cancer. Clin Cancer Res 1995; 1: 973
11. Anzano MA, Byers SW, Smith JM, et al. Prevention of breast cancer in the rat with 9-cis RA as a single agent and in combination with tamoxifen. Cancer Res 1994; 54 (17): 4614-7
12. Hill DL. Retinoids and cancer prevention. Annu Rev Nutr 1992; 12: 161-81
13. Huang ME, Yu-chen Y, Shu-rong C, et al. Use of all-trans retinoid acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72
14. Gillis JC, Goa KL. Tretinoin: a review of its pharmacodynamic and pharmacokinetic properties and use in the management of acute promyelocytic leukemia. Drugs 1995; 50 (5): 897-923
15. Frankel SR, Eardley A, Heller G, et al. All-trans retinoic acid for acute promyelocytic leukemia: results of the New York study. Ann Intern Med 1994; 120: 278-86
16. Warrell Jr RP, de-The H, Wang ZY, et al. Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177-89
17. Warrell RP. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies and implications. Blood 1993; 82 (7): 1949-53
18. Lefebvre P, Thomas G, Gourmel B, et al. Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. Leukemia 1991; 5: 1054-8
19. Muindi J, Frankel SR, Miller WH, et al. Continuous treatment with all-trans retinoic acid results in a progressive decrease in plasma concentrations: implications for relapse and retinoid 'resistance' in acute promyelocytic leukemia. Blood 1992; 79: 299-303
20. Adamson PC, Boylan JF, Balis FM, et al. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein. Cancer Research 1993; 53: 472-6
21. Pemrick SM, Lucas DA, Grippo JF. The retinoid receptors. Leukemia 1994; 8: 1797-806
22. Dermine S, Grignani F, Monica C, et al. Occurrence of resistance to retinoic acid in the acute promyelocytic leukemia cell line NB4 is associated with altered expression of the PML/RAR-α protein. Blood 1993; 82: 1573-7
23. De Ruyter MGM, De Leenheer AP. Retinoic acid, an endogenous compound of human blood: unequivocal demonstration of endogenous retinoic acid in normal physiological conditions. Anal Biochem 1979; 98: 402-9
24. McCormick AM, Napoli JM, DeLuca HF. High pressure liquid chromatography of vitamin A metabolites and analogs. Methods Enzymol 1980; 67: 220-33
25. Rissler K, Friedrich G. Determination of the retinoid (E)-1,2,3,4,-tetrahydro-1,1,4,4-tetramethyl-6-(1 methyl-2-phenylethenyl)naphtalene and its phenolic metabolite in human plasma by reversed-phase high performance liquid chromatography. J Chromatogr 1991; 565: 375-82
26. Noy N. The ionization behaviour of retinoic acid in aqueous environments and bound to serum albumin. Biochim Biophys Acta 1992; 1106: 152-8
27. Noy N. The ionization behaviour of retinoic acid in lipid bilayers and in membranes. Biochim Biophys Acta 1992; 1106: 159-64
28. Boylan JF, Gudas LJ. Overexpression of the cellular retinoic acid binding protein-I (CRABP-I) results in a reduction in differentiation specific gene expression in F9 teratocarcinoma cells. J Cell Biol 1991; 112: 965-70
29. Boylan JF, Rugas LJ. The level of CRABP I expression influences the amounts and types of all-trans retinoic acid metabolites in F9 teratocarcinoma stem cells. J Biol Chem 1992; 267: 21486-91
30. Kizaki M, Ikeda Y, Tanosaki R, et al. Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation and expression of retinoic acid receptor-α and retinoid X receptor-α RNA by HL-60 cells. Blood 1993; 12 (15): 3592-9
31. Goodman DS, Blaner WS. Biosynthesis, absorption and hepatic metabolism of retinol. In: Sporn MB, Roberts AB, Goodman DS, editors. The retinoids. Vol. 2. New York: Raven Press, 1984: 1-40
32. Fidge NH, Shiratori T, Ganguly J, et al. Pathway of absorption of retinal and retinoic acid in the rat. J Lipid Res 1968; 9: 103-9
33. Smith JK, Milch PO, Muto Y, et al. The plasma transport and metabolism of retinoic acid in the rat. Biochem J 1973; 132: 821-7
34. Kalin JR, Starling ME, Hill DE. Disposition of all-trans retinoic acid in mice following oral doses. Drug Metab Disp 1981; 9: 196-201
35. Eckhoff C, Collins MD, Nau H. Human plasma all-trans, 13 cis and 13-cis-4-oxo-retinoic acid profiles during subchronic vitamin A supplementation: comparison to retinol and retinyl ester plasma levels. J Nutr 1991; 121: 1016-25
36. Folman Y, Russell RM, Tang GW, et al. Rabbits fed on beta carotene have higher serum levels of all-trans retinoic acid than those receiving no beta carotene. Br J Nutr 1989; 62: 195-201
37. Napoli JL, Race KR. Biogenesis of retinoic acid from β-carotene. J Biol Chem 1988; 263: 17372-7
38. Posch KC, Boerman MHEM, Burns RD, et al. Holo-cellular retinol-binding proteins as a substrate for microsomal retinal synthesis. Biochemistry 1991; 30: 6224-30
39. Sporn MB, Roberts AB, Goodman DS. The retinoids: biology, chemistry and medicine. 2nd ed. New York: Raven Press Ltd, 1994
40. Eriksson U, Hansson E, Nordlinder H, et al. Quantitation and tissue localization of the cellular retinoic acid binding protein. J Cell Physiol 1987; 133: 482-9
41. Saari JC, Futterman S. Separable binding proteins for retinoic acid and retinol in bovine retina. J Biol Chem 1976; 253: 6432-6
42. Sundelin J, Das SR, Eriksson U, et al. The primary structure of bovine cellular retinoic acid-binding proteins. J Biol Chem 1985; 260: 6488-93
43. Chytil F, Page DL, Ong DE. Presence of cellular retinol and retinoic acid binding proteins in human huterus. Int J Vitam Nutr Res 1975; 45: 293-8
44. Elder JT, Astrom A, Pettersson U, et al. Differential regulation of retinoic acid receptors and binding proteins in human skin. J Invest Dermatol 1992; 98: 673-9
45. Petkovich M, Bran NJ, Krust A, et al. A human RA receptor which belongs to the family of nuclear receptors. Nature 1987; 330: 444-50
46. Mangelsdorf DJ, Ong ES, Dyck JA, et al. Nuclear receptor that identifies a novel RA response pathway. Nature 1990; 345: 224-9
47. Nepgal S, Saunders M, Kastner P, et al. Promoter context and response element-dependent specificity of the transcriptional activation and modulating functions of RA receptors. Cell 1992; 70: 1007-19
48. Blumberg B, Mangelsdorf DJ, Dyck JA, et al. Multiple retinoid-responsive receptors in a single cell: families of retinoid 'X' receptors and retinoic acid receptors in the xenopus egg. Proc Natl Acad Sci USA 1992; 89: 2321-5
49. Muindi JRF, Frankel SR, Huselton C, et al. Clinical pharmacology of oral all-trans-retinoic acid in patients with acute promyelocytic leukemia. Cancer Res 1992; 52: 2138-42
50. Muindi JRF, Young CW, Warrell RP. Clinical pharmacology of all-trans-retinoic acid. Leukemia 1994; 8: 1807-12
51. Smith MA, Adamson PC, Balis FM, et al. Phase I and pharmacokinetic evaluation of all-trans retinoic acid in pediatric patients with cancer. J Clin Oncol 1992; 10 (11) 1666-73
52. Lee JS, Newman RA, Lippman SM, et al. Phase I evaluation of all-trans retinoic acid in adults with solid tumors. J Clin Oncol 1993; 11 (85): 959-66
53. 2) in acute promyelocytic leukemia. Blood 1993; 82: 3560-3
54. Smith DC, Jacob HE, Lotze MT, et al. A phase I trial of interferon-α 2a (IFN-α) and all-trans retinoic acid (ATRA): a pharmacokinetic assessment. Proc Am Soc Clin Oncol 1994; 13: 134
55. Lee JS, Newman RA, Lippman SM, et al. Phase I evaluation of all-trans retinoic acid with and without ketokonazole in adults with solid tumors. J Clin Oncol 1995; 13 (6): 1501-8
56. Adamson PC, Bailey J, Pluda J, et al. Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 1995; 13: 1238-40
57. Adamson PC, Reaman G, Feusner J. Pediatric phase I trial and pharmacokinetic study of all-trans retinoic (ATRA) acid administered on an intermittenl schedule. Proc Am Soc Clin Oncol 1995; 14: 170
58. Toma S, Iacona I, Palumbo R, el al. Modulation of all-trans retinoic acid administered on intermittent schedule by α-interferon 2a in a patient with AIDS-related Kaposi's sarcoma. AIDS, 1996; 10 (9): 1049-50
59. El Mansouri S, Tod M, Leclerq M, et al. Time- and dose-dependent kinetics of all-trans retinoic acid in rats after oral or intravenous administration. Drug Metab Dispos 1995; 23 (2): 227-31
60. Adamson PC, Balis FM, Smith M A, et al. Dose-dependent pharmacokinetics of all-trans retinoic acid. J Natl Cancer Inst 1992; 84: 1332-5
61. Adamson PC. Pharmacokinetics of all-trans retinoic acid: clinical implications in acute promyelocytic leukemia. Semin Hematol 1994; 31 (5): 14-7
62. Data on file, F. Hoffmann-La Roche, Basel, Switzerland
63. Skare KL, Deluca HF. Biliary metabolites of all-trans-retinoic acid in the rat. Arch Biochem Biophys 1983; 224: 13-8
64. Zachman RD, Dunagin Jr PE, Olson JA. Formation and enterohepatic circulation of metabolites of retinol and retinoic acid in bile duct-cannulated rats. J Lipid Res 1966; 7: 3-9
65. Geison RL, Johnson BC. Studies on the in vivo metabolism of retinoic acid in the rat. Lipids 1970; 5: 371-8
66. Ito Y, Zile M, De Luca HF, et al. Metabolism of retinoic acid in vitamin A-deficient rats. Biochim Biophys Acta 1974; 369: 338-50
67. Adamson PC, Pitot HC, Balis F, et al. Variability in the oral bioavailability of all-trams retinoic acid. J Natl Cancer Inst 1993; 85: 993-6
68. Barua AB, Batres RO, Olson JA. Characterization of retinyl β-glucuronide in human blood. Am J Clin Nutr 1989; 50: 370-4
69. 3H] retinoic acid after an oral dose in rats. Biochem J 1991; 277: 527-31
70. Blaner WS, Hussain MM, Talmage DA, et al. Retinoids are actively metabolized in rabbit bone marrow. FASEB J 1991; 5: A717
71. Kakizuka A, Miller Jr WH, Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcriptional factor, PML. Cell 1991; 68: 663-74
72. de-Thé H, Lavau C, Marchio A, et al. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991; 66: 675-84
73. Sandberg JA, Eckhoff C, Nau H, et al. Pharmacokinetics of 13-cis, all-trans, 13-cis-4-oxo, and all-trans retinoic acid after intravenous administration in the cynomolglus monkeys. Drug Metab Disp 1994; 22 (1): 154-60
74. Fiorella PD, Napoli JL. Microsomal retinoic acid metabolism. J Biol Chem 1994; 269: 10538-44
75. Roberts AB, Nichols MD, Newton DL, et al. In vitro metabolism of retinoic acid in hamster intestine and liver. J Biol Chem 1979; 254: 6296-302
76. Frolik CA, Roberts AB, Tavela TE, et al. Isolation and identification of 4-hydroxy and 4-oxo retinoic acid: in vitro metabolites of all-trans retinoic acid in hamster trachea and liver. Biochemistry 1979; 18: 2092-7
77. Frolik CA, Roller PP, Roberts AB, et al. In vitro and in vivo metabolism of all-trans retinoic acid and 13-cis retinoic acid in hamster. J Biol Chem 1980; 225: 8057-62
78. Roberts AB, Lamb LC, Sporn MB. Metabolism of all-trans-retinoic acid in hamster liver microsomes: oxidation of 4-hydroxy- to 4-keto-retinoic acid. Arch Biochem Biophys 1980; 199: 374-83
79. Martini R, Murray M. Participation of 3A enzymes in rat hepatic microsomal retinoic acid 4-hydroxylation. Arch Biochem Biophys 1993; 303: 57-66
80. Van Wauwe J, Van Nyen G, Coene MC, et al. Liarozole, an inhibitor of retinoic acid metabolism exert retinoid-mimetic effects in vivo. J Pharmacol Exp Ther 1992; 261: 773-9
81. Roberts ES, Vaz ADN, Coon MJ. Role of isozymes of rabbit microsomal cytochrome P-450 in the metabolism of retinoic acid, retinol and retinal. Mol Pharmacol 1992; 41: 427-33
82. Leo MA, Lasker JM, Raucy JL, et al. Metabolism of retinol and retinoic acid by human liver cytochrome P-450IIC8. Arch Biochem Biophys 1989; 269: 305-12
83. Cornic M, Delva L, Castaigne S, et al. In vitro all-trans retinoic acid sensitivity and cellular retinoic acid binding protein levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia. Leukemia 1994; 8: 914-7
84. Vanden Bossche H, Willemsens G, Janssen PAJ. Cytochrome P-450-dependent metabolism of retinoic acid in rat skin microsomes: inhibition by ketoconazole. Skin Pharmacol 1988; 1: 176-85
85. Vanden Bossche H, Willemsens G. Retinoic acid and cytochrome P-450. In: Saurat JH, editor. Retinoids 10 years on. Basel: Karger, 1991: 79-88
86. Van Wauwee JP, Coene MC, Goossens J, et al. Ketoconazole inhibits the in vitro and in vivo metabolism of all-trans retinoic acid. J Pharmacol Exp Ther 1988; 245: 718-22
87. Van Wauwee JP, Coene MC, Goossens J, et al. Effects of cytochrome P-450 inhibitors on the in vivo metabolism of all-trans retinoic-acid in rats. J Pharmacol Exp Ther 1990; 252: 365-9
88. Adamson PC. Clinical and pharmacokinetic studies of all-trans retinoic acid in pediatric patients with cancer. Leukemia 1994; 8 (11): 1813-6
89. Fiorella PD, Napoli JL. Expression of cellular retinoic acid binding protein (CRABP) in Escherichia coli: characterization and evidence that holo CRABP is a substrate in retinoic acid metabolism. J Biol Chem 1991; 266: 16572-9
90. Tavakkol A, Griffith CEM, Keane KM, et al. Cellular localization of mRNA for cellular retinoic acid-binding protein II and nuclear retinoic acid receptor in retinoic-acid treated human skin. J Invest Dermatol 1992; 99: 146-50
91. Hirschel-Scholz S, Siegenthaler G, Saurat JH. Ligand specific and non-specific in vivo modulation of human epidermal cellular retinoic acid binding proteins (CRABP). Eur J Clin Invest 1989; 19: 220-7
92. Williams JB, Napoli JL. Metabolism of retinoic acid and retinol during differentiation of F9 embryonal carcinoma cells. Biochem Pharmacol 1985; 36: 1386-8
93. De Coster R, Wouters W, Van Ginckel R, et al. Experimental studies with liarozole (R 75251): an antitumoral agent which inhibits retinoic acid breakdown. J Steroid Biochem Mol Biol 1992; 43: 197-201
94. Goldfarb MT, Ellis CN, Voorhees JJ. Retinoids in dermatology. Mayo Clin Proc 1987; 62: 1161-4
95. Dijkman GA, Van Moorselaar RJA, Van Ginkel R, et al. Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomes. J Urol 1994; 151: 217-22
96. Rigas JR, Francis PA, Muindi JRF, et al. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketoconazole. J Natl Cancer Insl 1993; 85: 1921-6
97. Miller VA, Rigas JR, Muindi JR, et al. Modulation of all-trans retinoic acid pharmacokinetics by liarozole. Cancer Chemother Pharmacol 1994; 34 (6): 522-6
98. Westarp ME, Westarp MP, Bruynseels J, et al. Oral liarozole as a catabolic inhibitor potently increases retinoic acid in vivo: first experience from an ongoing therapeutic trial in highly malignant primary brain tumors. Onkologie 1993; 16: 22-5
99. Relling MV, Aoyama T, Gonzalez FJ, et al. Tolbutamide and mephenytoin hydroxylation by human cytochrome P-450s in the CYP2C subfamily. J Pharmacol Exp Ther 1990; 152: 442-7
100. Veronese ME, Miners JO, Randles D, et al. Validation of the tolbutamide metabolic ratio for population screening using sulphaphenazole to produce model phenotyping poor metabolisers. Clin Pharmacol Ther 1990; 47: 403-11
101. Pond SM, Birkett DJ, Wade DN. Mechanism of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Clin Pharmacol Ther 1977; 22: 573-9
102. Toma S. Monteghirfo S, Tasso P, et al. Antiproliferative and synergistic effect of interferon α-2a, retinoids and their association in established human cancer cell lines. Cancer Lett 1994; 82: 209-16
103. Okuno H, Kitao Y, Takasu M, et al. Depression of drug metabolizing activity in the human liver by interferon α. Eur J Clin Pharmacol 1990; 39: 365-7
104. Moor DM, Kalvakolanu DV, Lippman SM, et al. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol 1994; 31: 31-7
105. Israel BC, Blouin RA, McIntyre W, et al. Effect of interferon α monotherapy on hepatic drug metabolism in cancer patients. Br J Clin Pharmacol 1993; 36: 229-35
106. Lazzarino M, Corso A, Regazzi MB, et al. Modulation of all-trans retinoic acid pharmacokinetics in acute promyelocytic leukemia by prolonged interferon α therapy. Br J Haematol 1995; 90: 928-30
107. Bailey J, Pluda JM, Foli A, et al. Phase I/II study of intermittent all-trans-retinoic-acid alone and in combination with interferon alpha-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 1995; 13: 1966-74
108. Mehta K, Sadeghi T, McQueen T, et al. Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans retinoic acid. Leukemia Res 1994; 18 (8): 587-96
109. Gray A, Morgan J. Liposomes in haematology. Blood Rev 1991; 5: 258-72
110. Phillips NC, Tsoukas C. Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome. Blood 1992; 79: 1137-43
111. Drach J, Lopez-Berestein G, McQueen T, et al. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans retinoic acid. Cancer Res 1993; 53: 2100-4